Alto Neuroscience (ANRO) Non Operating Interest Expenses (2023 - 2026)
Powered by 
Analysis
Alto Neuroscience (ANRO) Non Operating Interest Expenses (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | 491,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 491,000.00 |
| Mar 31, 2026 | 545,000.00 |
| Dec 31, 2025 | 575,000.00 |
| Sep 30, 2025 | 650,000.00 |
| Jun 30, 2025 | 646,000.00 |
| Mar 31, 2025 | 598,000.00 |
| Dec 31, 2024 | 333,000.00 |
| Sep 30, 2024 | 349,000.00 |
| Jun 30, 2024 | 347,000.00 |
| Mar 31, 2024 | 346,000.00 |
| Dec 31, 2023 | 356,000.00 |
| Sep 30, 2023 | 363,000.00 |
| Jun 30, 2023 | 327,000.00 |
| Mar 31, 2023 | 324,000.00 |